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Abstract
Background
Hyperlipidemia and hypertension are modifiable risk factors for Alzheimer’s disease and
related dementias (ADRD). Approximately 25% of adults over age 65 use both antihyperten-
sives (AHTs) and statins for these conditions. While a growing body of evidence found stat-
ins and AHTs are independently associated with lower ADRD risk, no evidence exists on
simultaneous use for different drug class combinations and ADRD risk. Our primary objec-
tive was to compare ADRD risk associated with concurrent use of different combinations of
statins and antihypertensives.
Methods
In a retrospective cohort study (2007–2014), we analyzed 694,672 Medicare beneficiaries
in the United States (2,017,786 person-years) who concurrently used both statins and
AHTs. Using logistic regression adjusting for age, socioeconomic status and comorbidities,
we quantified incident ADRD diagnosis associated with concurrent use of different statin
molecules (atorvastatin, pravastatin, rosuvastatin, and simvastatin) and AHT drug classes
(two renin-angiotensin system (RAS)-acting AHTs, angiotensin converting enzyme inhibi-
tors (ACEIs) or angiotensin-II receptor blockers (ARBs), vs non-RAS-acting AHTs).
Findings
Pravastatin or rosuvastatin combined with RAS-acting AHTs reduce risk of ADRD relative to
any statin combined with non-RAS-acting AHTs: ACEI+pravastatin odds ratio (OR) = 0.942
(CI: 0.899–0.986, p = 0.011), ACEI+rosuvastatin OR = 0.841 (CI: 0.794–0.892, p<0.001),
ARB+pravastatin OR = 0.794 (CI: 0.748–0.843, p<0.001), ARB+rosuvastatin OR = 0.818
(CI: 0.765–0.874, p<0.001). ARBs combined with atorvastatin and simvastatin are
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Data Availability Statement: The primary data
source for the project is CMS Medicare claims
data. The CMS data used in this project cannot be
associated with smaller reductions in risk, and ACEI with no risk reduction, compared to
when combined with pravastatin or rosuvastatin. Among Hispanics, no combination of stat-
ins and RAS-acting AHTs reduces risk relative to combinations of statins and non-RAS-act-
ing AHTs. Among blacks using ACEI+rosuvastatin, ADRD odds were 33% lower compared
to blacks using other statins combined with non-RAS-acting AHTs (OR = 0.672 (CI: 0.548–
0.825, p<0.001)).
Conclusion
Among older Americans, use of pravastatin and rosuvastatin to treat hyperlipidemia is less
common than use of simvastatin and atorvastatin, however, in combination with RAS-acting
AHTs, particularly ARBs, they may be more effective at reducing risk of ADRD. The number
of Americans with ADRD may be reduced with drug treatments for vascular health that also
confer effects on ADRD.
Introduction
Alzheimer’s disease and related dementias (ADRD) are a large and growing public health
issue. There are approximately 7 million individuals aged 65 and older living with ADRD in
the United States, and this number is projected to grow to 12 million by 2040 [1]. With no dis-
ease-modifying treatments for ADRD, there has been increased global attention on prevention
and risk reduction of ADRD by maintenance of a healthy lifestyle and management of diseases
such as hypertension and dyslipidemia [2–5]. A reduction in risk of ADRD would bring signif-
icant health and financial benefits to individuals, societies, and families [6].
Antihypertensive therapies are effective pharmaceutical treatments for hypertension, and
statins for dyslipidemia. Statins are hypothesized to act on Alzheimer’s disease (AD) pathology
through their effect on cholesterol as well as through other nonlipid effects such as reduced
inflammation, although heterogeneity in molecular structure, efficacy, and pharmacokinetics
across statins suggests potential variability in effects [7–12]. Randomized controlled trials and
reviews in this area have failed to find a beneficial effect of statins on AD, although limitations
of these studies (e.g., short follow-up periods, non-representative samples, and removal of
hyperlipidemic subjects) are well recognized [13–15]. There is, however, a growing body of
observational evidence showing that statins are associated with reduced ADRD risk [16–22],
including our own work that featured robust control for confounding in a large and represen-
tative dataset [16]. Recent evidence also suggests that some subgroups may be more responsive
to statin therapy than others [23, 24]. Though potential influence of statins on AD pathology is
still unclear, some trials suggest statin-related attenuation of tau in middle age participants,
which aligns with the findings from a community based-autopsy cohort [25, 26].
Systematic analysis of observational, randomized controlled trials, and meta-analyses found
AHT treatment was protective against cognitive decline and incident dementia [27–30]. Sev-
eral studies have implicated the renin-angiotensin system (RAS) in AD, in particular over-acti-
vation of the classical hypertension-promoting RAS (cRAS), and more recently dysfunction of
the regulatory RAS (rRAS), which ordinarily regulates cRAS activity [31–37]. A recent study
confirmed these results and reported that RAS AHT users (vs. other AHT users) exhibited
fewer neurofibrillary tangles in predetermined brain regions involved in AD [38]. These find-
ings are consistent with hypotheses that therapeutic classes of AHTs operating to reduce RAS
activity (i.e., angiotensin converting enzyme inhibitors (ACEIs) and angiotensin-II receptor
blockers (ARBs)), may affect AD differently than other AHT drug classes (e.g., calcium
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channel blockers, beta blockers, loop diuretics, or thiazide diuretics) [39–41]. Moreover, in
vitro and animal studies of AD show that ARBs were more protective than ACEIs because of
ACEI’s potential role in amyloid-beta degradation, and in Tg2576 mice that enhancement of
rRAS can prevent and reverse cognitive decline and reduce amyloid-beta pathology [35, 40,
42, 43]. Our recent observational study confirmed this relationship in a longitudinal, popula-
tion study [44].
Approximately one quarter of older Americans used both a statin and an AHT in 2014.
Despite the high prevalence of use and hypothesized variation in effects across different types
of statins and AHTs, there are no existing analyses of the association of use of specific combi-
nations of AHT and statins and ADRD risk. The widespread use of these drugs increases the
importance of analyses examining the combinations of therapies that are associated with the
greatest and least reduction in ADRD risk and for specific populations. The purpose of this
study is to use data from a large population-based cohort to examine the hypothesis that some
combinations of statins and AHTs may be more protective against ADRD onset than others,
and analyze variation by sex and race/ethnicity in order to inform about the potential for pop-
ulation-specific health benefits.
Methods
Data
We examined the medical and pharmacy claims of a random 20% sample of Medicare benefi-
ciaries, aged 67 and higher, enrolled in traditional Medicare (fee-for-service) from 2007 to
2014. Medicare is publicly funded health insurance in the United States for individuals aged 65
and higher, as well younger beneficiaries with certain permanent disabilities. As of 2018, there
were approximately 60 million enrollees in Medicare, two thirds of whom had traditional (fee-
for-service) Medicare (as opposed to Medicare Advantage, a privately administered alterna-
tive) [45]. Traditional Medicare tends to enroll slightly less healthy beneficiaries than Medicare
Advantage, but still comprise a majority of older adults in the United States, with nationwide
representativeness [45]. We linked claims from Medicare Parts A (inpatient care), B (outpa-
tient care), and D (prescription drugs) to enrollment files that included beneficiaries’ charac-
teristics. Part D claims include key elements related to prescription drug utilization, while
Parts A and B claims capture include detailed diagnosis and procedure codes (International
Classification of Diseases, Ninth Revision (ICD-9)). These data were further supplemented with
claims histories from the Chronic Conditions Warehouse. Institutional review board approval
was granted by the University of Southern California University Park IRB, which granted a
waiver of participant consent under 45 CFR 46.116(d).
Study sample
The study sample consisted of person-years for Medicare beneficiaries age 67 and older. In
each person-year, we required observation for a minimum of three years (that year and the
previous two) with consecutive fee-for-service enrollment, Part D enrollment, and no death.
Individuals were required to have used both an AHT and a statin for the two previous years,
have no prior ADRD diagnoses, and no prior use of AD specific medications (acetylcholines-
terase inhibitors (AChEIs) or memantine). ICD-9 codes are specified in S1 Appendix. The
analytic sample consisted of 694,672 unique beneficiaries, followed for a total of 2,017,786 per-
son-years (1,241,491 for females, and 776,295 for males). Table 1 shows the characteristics of
the analytic sample.
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Measuring statin and AHT exposure
We identified AHT and statin use in Medicare Part D prescription drug claims (2007–2013).
AHT use was for the following classes: angiotensin-converting enzyme inhibitors (ACEI),
angiotensin-II receptor blockers (ARB), beta-blockers (BBL), calcium channel blockers (CCB),
loop diuretics (LDs), and thiazide-like diuretics (TDs). Statin use was for the following mole-
cules: atorvastatin, pravastatin, rosuvastatin, and simvastatin, which were the four most com-
monly used molecules in these data. We defined combination AHT and statin users as any
individual with 90 days supply and at least two claims in a year for both types of drugs for the
two previous years. This threshold was chosen as the minimum necessary to ensure regular
use of the drug during the exposure period, and is consistent with the definitions used in ear-
lier evidence [44]. We examined robustness of results to other definitions of use: 180 days and
2 claims, 270 days and 2 claims.
Study design
In a retrospective cohort design, we compared onset of ADRD separately for RAS-acting ACEI
and ARB therapies combined with each different molecule of statin, to onset among persons
using other combinations of non-RAS acting AHTs and statins. Onset of ADRD was measured
using index date of ADRD diagnosis and we required an ADRD index diagnosis to be verified
with either a second ADRD diagnosis code or ‘dementia specified elsewhere’ diagnosis code in
a subsequent claim within the study period (2009–2014). Measurement error in the timing of
Table 1. Characteristics of combination statin and AHT users in 2009–2014 Medicare claims data.
RAS + any
statin
Non-RAS AHT + any
statin
ACEI
+ ator
ACEI
+ pra
ACEI
+ rosu
ACEI
+ sim
ARB
+ ator
ARB + pra ARB
+ rosu
ARB
+ sim
ADRD 2.07% 2.64% 2.18% 2.03% 1.63% 2.16% 2.02% 1.94% 1.62% 2.02%
Age 77.3 78.0 77.2 77.2 76.2 77.1 77.6 77.8 76.7 77.6
Female 61% 63% 56% 60% 56% 57% 66% 70% 67% 68%
White 83% 86% 84% 86% 84% 85% 78% 82% 78% 79%
Black 6% 6% 6% 7% 7% 6% 7% 7% 6% 7%
Hispanic 6% 4% 6% 4% 6% 5% 7% 5% 8% 7%
Other race 5% 4% 4% 3% 3% 3% 9% 6% 8% 7%
% HS grad 76% 76% 76% 75% 75% 76% 76% 76% 75% 76%
Median income $55,745 $55,919 $56,728 $53,436 $54,187 $54,208 $59,299 $55,548 $56,784 $56,319
# physician
visits
9.5 9.9 9.1 9.2 9.9 8.7 10.7 10.8 11.6 10.1
HCC 1.25 1.33 1.26 1.24 1.25 1.24 1.28 1.26 1.26 1.26
AMI 9% 9% 10% 8% 10% 9% 8% 7% 8% 7%
ATF 18% 23% 18% 19% 18% 17% 18% 19% 17% 17%
Diabetes 53% 40% 52% 51% 54% 53% 55% 52% 57% 54%
Stroke 16% 18% 16% 17% 16% 16% 17% 17% 17% 16%
Beneficiaries 507,304 279,398 92,551 48,545 35,128 173,653 60,569 29,250 27,259 95,007
Observations 1,387,009 630,777 214,734 106,203 78,620 435,902 140,609 62,749 61,080 231,174
Sample of 2009–2014 Medicare person-years with 90 possession days and 2 claims of both an AHT and a statin in both years t-1 and t-2. RAS (renin-angiotensin
system) AHTs are antihypertensive (AHT) prescription drugs (angiotensin converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs). Non-
RAS acting AHTs are beta-blockers, calcium channel blockers, loop diuretics, and thiazide diuretics. Statins are atorvastatin, pravastatin, rosuvastatin, and simvastatin.
Sample restricted to person-years with 3 years fee-for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior ADRD diagnoses, and no prior
use of acetylcholinesterase inhibitors (AChEIs) or memantine. Abbrevations: ADRD (Alzheimer’s disease and related dementias), HS (high school), HCC (Hierarchical
Condition Category index), AMI (acute myocardial infarction), ATF (atrial fibrillation).
https://doi.org/10.1371/journal.pone.0229541.t001
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ADRD diagnosis is unlikely to bias our results because the same error exists for subjects in
both the exposure and comparator groups. To mitigate concern that imminent ADRD onset
could lead to poor adherence or discontinuation of AHT use, we designated years t-1 and t-2
as the drug exposure years, prior to assessing ADRD risk in year t. For example, we relate
AHT/statin use in 2007–2008 to ADRD risk in 2009; in the absence of an ADRD diagnosis, the
same individual remains in the sample and their AHT/statin use in 2008–2009 is related to
their ADRD incidence in 2010, and further, as long as they continue to meet the inclusion/
exclusion criteria. Sex and race/ethnicity specific analyses use only members of the same sex or
race/ethnicity as the comparison group; thus estimated differences in association across com-
binations is attributed to the drugs and not due to unobserved differences across sex or race/
ethnicity.
Statistical analyses
We examined the association of combination AHT and statin use (in years t-1 and t-2) and
incident ADRD (year t), during the years 2009 to 2014. We used multivariable logistic regres-
sion to control for the potentially confounding roles of age, age squared, sex, race, proxy mea-
sures of socio-economic status (high school graduation rate within the beneficiary’s zip code
(quartiles), zip code median income (quartiles)), years since hypertension and hyperlipidemia
diagnoses, comorbidity index (quartiles), number of physician visits (quartiles), and indicators
for past diagnoses of diabetes, atrial fibrillation, acute myocardial infarction, and stroke. Time-
varying covariates were measured in year t-1. Health status was measured with past diagnosis
of key comorbidities, as well as the Centers for Medicaid and Medicare Services-Hierarchical
Condition Category (CMS-HCC), an index based on health status from diagnostic data and
demographics, in which higher numbers indicate worse health. The CMS uses this index to
predict health expenditures in the next year, and it correlates highly with mortality [46]. We
used years since hypertension and hyperlipemia diagnoses, as measured by the Chronic Con-
ditions Warehouse (CCW) as far back as 1999, to control for unobserved AHT and statin use
in the years prior to Medicare Part D enactment in 2006. Race/ethnicity was determined with
the beneficiary race code in CMS enrollment data, and with the application of a name-based
identification algorithm from the Research Triangle Institute [47]. Standard errors were clus-
tered at the county level. We ran analyses for the sample as a whole, as well as for each sex and
for different racial/ethnic populations.
Results
Table 1 depicts the characteristics of our analytic sample. The annual ADRD incidence rate in
this sample is 2.07% among persons using a RAS-acting AHT and any statin, and 2.64%
among persons using a non-RAS-acting AHT and any statin. Generally, rates were lower per-
sons using ARBs compared to ACEI with the exception of no difference in rates among per-
sons using them in combination with rosuvastatin. Those using a RAS-acting AHT were
younger, more likely to be male, non-white, and have a lower mean HCC score. There were no
differences in percent high school graduate or median income. ACEI users compared to ARB
users, across statin types, are about 0.5 years younger, more likely to be male, white, and have
fewer physician visits, and lower HCC scores. There were no differences in percent high school
graduate or median income.
Fig 1 reports odd ratios (ORs) and 95% confidence intervals from logistic regressions of
ADRD incidence that adjust for the patient and setting characteristics described above. Com-
pared to individuals using statins combined with non-RAS AHTs, use of pravastatin and rosu-
vastatin in combination of ARB or ACEI was associated with reduced risk of ADRD (ACEI
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+pravastatin OR = 0.942 (CI: 0.899–0.986, p = 0.011), ACEI+rosuvastatin OR = 0.841 (CI:
0.794–0.892, p<0.001), ARB+pravastatin OR = 0.794 (CI: 0.748–0.843, p<0.001), ARB+-
rosuvastatin OR = 0.818 (CI: 0.765–0.874, p<0.001)). There was no reduced risk associated
with ACEI use and either atorvastatin or simvastatin, but a reduced risk when combined with
ARBs (ARB+atorvastatin OR = 0.896 (CI: 0.861–0.932, p<0.001), ARB+simvastatin
OR = 0.877 (CI: 0.848–0.908, p<0.001)).
Table 2 reports results of ORs separately for men and women. Combined use of ACEIs with
three statins (atorvastatin, simvastatin, and pravastatin), compared to combined use statins
and non-RAS-acting AHTs, was not associated with reduced ADRD risk among women.
ACEI+rosuvastatin and ARB+rosuvastatin were associated with lower odds of ADRD among
women (ACEI+rosuvastatin OR = 0.832 (CI: 0.776–0.892, p<0.001), ARB+rosuvastatin
OR = 0.833 (CI: 0.774–0.895, p<0.001). Among men, with the exception of simvastatin, com-
bine use of any statin and either ACEI or ARB was associated with lower odds of ADRD
incidence.
Table 2 also reports results of ORs separately by race/ethnicity. Among Hispanics, there is
no combination of statins and RAS-acting AHTs compared to combinations of statins and
Fig 1. Adjusted odds ratios of ADRD incidence associated with use of statin-AHT combinations, relative to users of other statin-
AHT combinations, with 95% confidence intervals. Logistic regression results for ADRD incidence in sample of 2009–2014 Medicare
person-years (N = 2,017,786) with 90 possession days and 2 claims of both an AHT and a statin in both years t-1 and t-2. AHTs are
antihypertensive (AHT) prescription drugs (angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II receptor blockers
(ARBs), beta-blockers, calcium channel blockers, loop diuretics, and thiazide diuretics), and statins are atorvastatin, pravastatin,
rosuvastatin, and simvastatin. Sample restricted to person-years with 3 years fee-for-service, 3 years Part D, age 67+, no deaths in the
reference year (year t), no prior ADRD diagnoses, and no prior use of acetylcholinesterase inhibitors (AChEIs) or memantine. Controls
are age, age squared, sex, education, income quartiles, statin use (t-1), years since hypertension and hyperlipidemic diagnoses, HCC
comorbidity index, number of physician visits, and indicators for past diagnoses of diabetes, atrial fibrillation, acute myocardial
infarction, and stroke. Standard errors are clustered at the county level.
https://doi.org/10.1371/journal.pone.0229541.g001
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non-RAS acting AHTs that is associated with lower risk of ADRD. Among blacks, the reduced
risk associated with combined use of rosuvastatin and ACEI is large (OR = 0.672, CI: 0.548–
0.825, p<0.001). Among blacks there is also reduced risk associated with combined use of sim-
vastatin and ARBs (OR = 0.856, CI: 0.763–0.960, p = 0.008), atorvastatin and ARBs
(OR = 0.869, CI: 0.757–0.999, p = 0.048), and pravastatin and ARBs (OR = 0.770, CI: 0.620–
0.956, p = 0.018). Among whites, combined use of ARBs and any statin is associated with
lower odds of ADRD relative to non-RAS acting AHTs and any statin.
Discussion
In this study, we examined the association between use of combined statin and RAS-acting
AHT drug therapies and ADRD risk, compared to risk associated with combined statin and
non-RAS acting AHT therapy. RAS-acting AHTs were disaggregated into ACEIs and ARBs,
and statins were disaggregated by molecule (atorvastatin, pravastatin, rosuvastatin, and
Table 2. Adjusted odds ratios of ADRD incidence associated with use of statin-AHT combinations, relative to users of other statin-AHT combinations.
Statin AHT Female Male White Black Hispanic
Ator ACEI OR 1.021 0.916 0.984 0.983 1.009
CI (0.983–1.060) (0.868–0.966) (0.951–1.019) (0.864–1.117) (0.899–1.132)
p 0.291 0.001 0.365 0.788 0.878
Sim ACEI OR 0.989 0.962 0.981 0.946 0.941
CI (0.957–1.022) (0.921–1.005) (0.953–1.009) (0.872–1.027) (0.862–1.028)
p 0.499 0.082 0.180 0.187 0.180
Pra ACEI OR 0.981 0.854 0.944 0.877 0.958
CI (0.927–1.038) (0.787–0.926) (0.897–0.992) (0.738–1.043) (0.784–1.169)
p 0.504 <0.001 0.024 0.137 0.671
Rosu ACEI OR 0.832 0.858 0.848 0.672 0.902
CI (0.776–0.892) (0.777–0.949) (0.795–0.905) (0.548–0.825) (0.753–1.080)
p <0.001 0.003 <0.001 <0.001 0.261
Ator ARB OR 0.902 0.883 0.902 0.869 0.869
CI (0.862–0.945) (0.819–0.953) (0.863–0.942) (0.757–0.999) (0.744–1.014)
p <0.001 0.001 <0.001 0.048 0.074
Sim ARB OR 0.893 0.837 0.878 0.856 0.898
CI (0.860–0.928) (0.785–0.893) (0.846–0.911) (0.763–0.960) (0.802–1.005)
p <0.001 <0.001 <0.001 0.008 0.060
Pra ARB OR 0.824 0.703 0.797 0.770 0.877
CI (0.771–0.881) (0.615–0.804) (0.746–0.852) (0.620–0.956) (0.685–1.121)
p <0.001 <0.001 <0.001 0.018 0.294
Rosu ARB OR 0.833 0.784 0.798 0.902 0.842
CI (0.774–0.895) (0.684–0.900) (0.742–0.858) (0.735–1.106) (0.692–1.025)
p <0.001 0.001 <0.001 0.320 0.086
N 1,241,491 776,295 1,689,066 125,843 106,019
Logistic regression results for ADRD incidence in sample of 2009–2014 Medicare person-years with 90 possession days and 2 claims of both an AHT and a statin in both
years t-1 and t-2. AHTs are antihypertensive (AHT) prescription drugs (angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs),
beta-blockers, calcium channel blockers, loop diuretics, and thiazide diuretics), and statins are atorvastatin, pravastatin, rosuvastatin, and simvastatin. Sample restricted
to person-years with 3 years fee-for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior ADRD diagnoses, and no prior use of
acetylcholinesterase inhibitors (AChEIs) or memantine. Controls are age, age squared, sex, education, income quartiles, statin use (t-1), years since hypertension and
hyperlipidemic diagnoses, HCC comorbidity index, number of physician visits, and indicators for past diagnoses of diabetes, atrial fibrillation, acute myocardial
infarction, and stroke. Standard errors are clustered at the county level.
https://doi.org/10.1371/journal.pone.0229541.t002
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simvastatin). No previous study has investigated the association of different combinations of
these frequently used drugs and ADRD risk in a large and broadly representative sample of
older Americans and across sex and racial and ethnic subpopulations. Among elderly adults,
who were using drugs to treat hypertension and dyslipidemia we found substantial variation in
ADRD risk reductions across different combinations of statins and AHTs, and across different
populations. The greatest reductions, as compared to individuals using statins and non-RAS
acting AHTs, were for individuals using ARBs in combination with pravastatin or rosuvasta-
tin. These results were robust to varying definitions of drug use (90, 180, and 270 days) (S2
and S3 Tables). This finding held in some subpopulations: women, men, whites, and blacks.
Our detection of significant reduction in ADRD risk for black men using specific combina-
tions of statins and RAS-acting AHTs is important, as this group was not previously found to
benefit from either statin therapy or RAS-acting AHT therapy [16, 44].
The magnitudes of estimated risk reductions were meaningful; for example, using ARBs
combined with pravastatin was associated with 21% lower odds of ADRD, as compared to
individuals using other statins and non-RAS acting AHTs in combination (OR = 0.794, CI:
0.748–0.843, p<0.001). As for users of ACEIs, the other RAS-acting AHT, only in combination
with rosuvastatin was there an associated reduction in risk of ADRD among older American
populations of women, men, whites, and blacks as compared to those same populations using
statins and non-RAS acting AHTs. This association was robust to varying definitions of use
(90, 180, and 270 days) (S2 and S3 Tables). While our results show greater protection for com-
binations that involve rosuvastatin or pravastatin, these drugs are not as frequently used as
atorvastatin and simvastatin. In 2007, 2.9% of Medicare beneficiaries with fee-for-service
(FFS) and Part D used pravastatin, and 3.3% used rosuvastatin, compared to 15.6% for atorva-
statin, and 18.1% for simvastatin (Fig 2). Use of rosuvastatin and pravastatin has grown over
time to 8.9% and 5.8% in 2014 for pravastatin and rosuvastatin, respectively (Fig 2). Rosuvasta-
tin has shown strong growth in market share since its branded version, Crestor, lost patent
protection in the United States in 2016 [48]. In 2017, rosuvastatin was the sixth fastest growing
mail and retail prescription in the U.S., with an additional 6.8 million 90-day equivalent pre-
scriptions [49]. The pharmacokinetics and pharmacodynamics of rosuvastatin are distinct
from other statins, and may be a contributing factor to the differences we found [50, 51]. Rosu-
vastatin appears to have preferential benefit over other statins with respect to favorable low-
density lipoprotein (LDL) cholesterol-lowering efficacy, as well as lower likelihood of side
effects due t low extra-hepatic penetration and interference with cytochrome P450 related
drug interactions [51]. In the ARIES trial, rosuvastatin improved the overall lipid profile of
hypercholesterolemic African-Americans better than the milligram-equivalent doses of atorva-
statin [52]. As the use of these molecules increases, additional benefits may be conferred for
older adults of diverse backgrounds.
In this study we cannot test what mechanisms are driving the differential associations that
were observed between the four statins investigated, all of which work to reduce low-density
lipoprotein (LDL) cholesterol levels, and combinations of ARBs or ACEIs. A potential mecha-
nism, and one that may explain some of the ethnic differences observed, are differences in
drug metabolism and transport. Rosuvastatin, for example, is metabolized by CYP2C9 and
CYP2C19 cytochrome P-450 enzymes. These CYP enzymes could be related to differential
associations with ADRD in two ways. First, if there are pharmacokinetic interactions between
certain statins and certain AHTs, the metabolism of one or both drugs could be altered in a
way that confers differential benefit regarding ADRD. CYP2C9, for example, metabolizes
Rosuvastatin, and is a substrate for several ARBs (e.g., losartan and irbesartan), potentially
leading to interactions [53]. Second, statins and/or AHTs may affect the activity of CYP
enzymes that have a direct impact on ADRD risk factors. For example, some genetic variants
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in CYP2C19 confer protection against amyloid-beta burden in persons with AD [54]. Addi-
tionally, CYP2C9 is encoded for by a gene previously linked to familial AD [55].
Atorvastatin and simvastatin, while failing to show a protective association against ADRD
when combined with ACEIs (compared to other combinations of statins and AHTs), were
observed to be protective when combined with ARBs. This might be due to an interaction
effect with ARBs on metabolism and transport, similar to what was described for rosuvastatin
and ARBs. While they are different in their duration of action (atorvastatin is a long acting
statin and simvastatin is a short acting one), both are metabolized by CYP3A4 that has, as with
CYP2C9, been shown to have common ARBs as a substrate [53]. The observed variability of
benefit may therefore be highlighting underlying differences in some of the drug metabolic
processes of these statins. Additionally, these enzymes are encoded by several genes, many of
which (e.g., CYP3A4, CYP2D6, CYP2C19) are polymorphic with variable prevalence of differ-
ent alleles that normally affect metabolizing phenotype in different race/ethnicities [56, 57];
while there is some evidence supporting CYP3A4 variant statin metabolism [56], the clinical
significance of these in relation to the drugs studied is unclear. Furthermore, some of the
observed differences in protection across race/ethnicity could be caused by differences in the
endogenous sodium and renin levels in the peripheral RAS, as was discussed in our earlier
work on this subject [44].
The strong protective association of pravastatin is difficult to explain. It is metabolized by
glucuronidation rather than cytochrome P450 metabolism [58], and while metabolic changes
are often reported in AD [59], it is not clear whether there are any disease-related differences
in glucuronidation in AD that might influence how pravastatin is metabolized.
There is some evidence that a net effect of reducing the formation of very low density lipo-
proteins (VLDLs), precursors of LDLs, can increase levels of LDL receptors [60]. One receptor
that might be similarly affected is LRP1, a receptor of VLDLs but also a major factor in recep-
tor-mediated clearance of amyloid-beta in AD [61]. Whether this would be a peripheral or
central effect is not determined.
Fig 2. Percent of Medicare beneficiaries with use of selected statin and antihypertensive prescription drugs, 2007–2014. Sample is Medicare beneficiaries
with fee-for-service and Part D coverage in the year of the horizontal axis. Use of a drug is defined as 90 days and 2 claims. Abbreviations: ACEI (angiotensin
converting enzyme inhibitors), ARB (angiotensin-II receptor blockers), RAS (renin-angiotensin system), non-RAS AHTs (beta-blockers, calcium channel
blockers, loop diuretics, and thiazide diuretics).
https://doi.org/10.1371/journal.pone.0229541.g002
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Dyslipidemia and hypertension are both independent risk factors of ADRD, and control of
both via lifestyle and medications has been associated with lower incidence and prevalence of
ADRD. Recent results from the SPRINT MIND trial found that aggressive blood pressure con-
trol (120 mmHg, vs less than 140 mm Hg) was associated with smaller increases in white mat-
ter lesion volume [62]. While the present study was not able to address variation in clinical
values of blood pressure, we found that hypertension treatment with RAS-acting AHTs plus
certain statins may confer ADRD related brain benefits beyond peripheral control of vascular
disease.
In addition to controlling blood pressure, RAS medications and to a greater extent ARBs,
improve endothelial function, insulin response, and decrease inflammation. Combined statin-
based and RAS inhibitor therapies demonstrate additive/synergistic beneficial effects on endo-
thelial dysfunction, insulin resistance, and other metabolic parameters in addition to lowering
both cholesterol levels and blood pressure. Mechanistically, the combination of reduced
inflammation, improved blood brain barrier integrity, and improved metabolic health all pro-
vide a reasonable rationale for reduced risk of ADRD in persons using combined statins and
ARBs.
This study has limitations. First, there is a possibility of confounding by indication, wherein
individuals who may be differentially predisposed toward ADRD risk are sorted into certain
combinations of statins and AHTs. Our study adjusted for many sources of possible bias, but
the possibility of unmeasured bias remains. Second, use of AHTs and statins could be impre-
cisely measured. We analyze robustness of results to different (higher) thresholds of days of
use. Drug use in the years prior to Medicare Part D (pre-2006) could confound analyses, if it
varies across our comparison groups (different combinations of drugs). Accordingly, we adjust
models for years since hypertension and hyperlipidemia diagnoses. Another source of mea-
surement error may be due to individuals switching between molecules or classes within a
year, but this would bias results toward zero. Third, timing of ADRD diagnoses in claims data
may not represent the true onset of the condition. However, our sample is all users of statins
and AHTs and there is no evidence to suggest that diagnostic practices would vary by different
combination of statins and AHTs, and therefore imprecise diagnoses would not bias the
results. Fourth, the sample is restricted to Medicare beneficiaries enrolled in FFS and Part D
(approximately two thirds of Medicare beneficiaries), and thus excludes those in Medicare
Advantage or in FFS and not enrolled in Part D, who tend to be slightly healthier on average
[45]. Finally, with these data, we cannot test the hypotheses of the various potential mecha-
nisms that may explain the variation by molecule and drug class, and by race and ethnicity
that we observed.
Conclusion
Nearly a quarter of the elderly in the U.S. use both statins and AHTs to treat or prevent dyslipi-
demia, hypertension, and cardiovascular disease. We found that RAS-acting ARBs combined
with pravastatin or rosuvastatin reduced ADRD risk reductions more than statins combined
with non-RAS acting AHTs, which may reflect or be dependent on underlying gene polymor-
phism-associated differences in drug metabolic processes. If these findings are replicated, spe-
cific combinations of statins and antihypertensives might be recommended in the interest of
reducing ADRD risk. Fewer older adults use pravastatin and rosuvastatin than other simva-
statin and atorvastatin. Over time, use of pravastatin and rosuvastatin and ARBs have
increased, potentially conferring population benefits of reduced dementia risk.
PLOS ONE Combination statin and antihypertensive therapy and Alzheimer’s disease and related dementia risk
PLOS ONE | https://doi.org/10.1371/journal.pone.0229541 March 4, 2020 10 / 15
Supporting information
S1 Appendix. Summary of ICD-9 codes used to define various diagnoses and symptoms.
(DOCX)
S1 Table. Adjusted odds ratios of AD incidence associated with use of statin-AHT combi-
nations, relative to users of other statin-AHT combinations. Logistic regression results for
AD incidence in sample of 2009–2014 Medicare person-years with 90 possession days and 2
claims of both an AHT and a statin in both years t-1 and t-2. AHTs are antihypertensive
(AHT) prescription drugs (angiotensin converting enzyme inhibitors (ACEIs), angiotensin-II
receptor blockers (ARBs), beta-blockers, calcium channel blockers, loop diuretics, and thiazide
diuretics), and statins are atorvastatin, pravastatin, rosuvastatin, and simvastatin. Sample
restricted to person-years with 3 years fee-for-service, 3 years Part D, age 67+, no deaths in the
reference year (year t), no prior AD diagnoses, and no prior use of acetylcholinesterase inhibi-
tors (AChEIs) or memantine. Controls are age, age squared, sex, education, income quartiles,
statin use (t-1), years since hypertension and hyperlipidemic diagnoses, HCC comorbidity
index, number of physician visits, and indicators for past diagnoses of diabetes, atrial fibrilla-
tion, acute myocardial infarction, and stroke. Standard errors are clustered at the county level.
(DOCX)
S2 Table. Adjusted odds ratios of ADRD incidence associated with use of statin-AHT com-
binations, relative to users of other statin-AHT combinations, with use defined as 180 days
and 2 claims. Logistic regression results for ADRD incidence in sample of 2009–2014 Medi-
care person-years with 180 possession days and 2 claims of both an AHT and a statin in both
years t-1 and t-2. AHTs are antihypertensive (AHT) prescription drugs (angiotensin convert-
ing enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), beta-blockers, cal-
cium channel blockers, loop diuretics, and thiazide diuretics), and statins are atorvastatin,
pravastatin, rosuvastatin, and simvastatin. Sample restricted to person-years with 3 years fee-
for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior ADRD
diagnoses, and no prior use of acetylcholinesterase inhibitors (AChEIs) or memantine. Con-
trols are age, age squared, sex, education, income quartiles, statin use (t-1), years since hyper-
tension and hyperlipidemic diagnoses, HCC comorbidity index, number of physician visits,
and indicators for past diagnoses of diabetes, atrial fibrillation, acute myocardial infarction,
and stroke. Standard errors are clustered at the county level.
(DOCX)
S3 Table. Adjusted odds ratios of ADRD incidence associated with use of statin-AHT com-
binations, relative to users of other statin-AHT combinations, with use defined as 270 days
and 2 claims. Logistic regression results for ADRD incidence in sample of 2009–2014 Medi-
care person-years with 270 possession days and 2 claims of both an AHT and a statin in both
years t-1 and t-2. AHTs are antihypertensive (AHT) prescription drugs (angiotensin convert-
ing enzyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), beta-blockers, cal-
cium channel blockers, loop diuretics, and thiazide diuretics), and statins are atorvastatin,
pravastatin, rosuvastatin, and simvastatin. Sample restricted to person-years with 3 years fee-
for-service, 3 years Part D, age 67+, no deaths in the reference year (year t), no prior ADRD
diagnoses, and no prior use of acetylcholinesterase inhibitors (AChEIs) or memantine. Con-
trols are age, age squared, sex, education, income quartiles, statin use (t-1), years since hyper-
tension and hyperlipidemic diagnoses, HCC comorbidity index, number of physician visits,
and indicators for past diagnoses of diabetes, atrial fibrillation, acute myocardial infarction,
and stroke. Standard errors are clustered at the county level.
(DOCX)
PLOS ONE Combination statin and antihypertensive therapy and Alzheimer’s disease and related dementia risk
PLOS ONE | https://doi.org/10.1371/journal.pone.0229541 March 4, 2020 11 / 15
Author Contributions
Conceptualization: Douglas Barthold, Geoffrey Joyce, Roberta Diaz Brinton, Whitney Whar-
ton, Patrick Gavin Kehoe, Julie Zissimopoulos.
Data curation: Douglas Barthold.
Formal analysis: Douglas Barthold, Geoffrey Joyce, Julie Zissimopoulos.
Funding acquisition: Douglas Barthold, Geoffrey Joyce, Roberta Diaz Brinton, Julie
Zissimopoulos.
Investigation: Douglas Barthold, Geoffrey Joyce, Roberta Diaz Brinton, Whitney Wharton,
Patrick Gavin Kehoe, Julie Zissimopoulos.
Methodology: Douglas Barthold, Geoffrey Joyce, Julie Zissimopoulos.
Supervision: Geoffrey Joyce, Julie Zissimopoulos.
Validation: Douglas Barthold, Geoffrey Joyce, Julie Zissimopoulos.
Visualization: Douglas Barthold, Geoffrey Joyce, Julie Zissimopoulos.
Writing – original draft: Douglas Barthold, Geoffrey Joyce, Julie Zissimopoulos.
Writing – review & editing: Douglas Barthold, Geoffrey Joyce, Roberta Diaz Brinton, Whit-
ney Wharton, Patrick Gavin Kehoe, Julie Zissimopoulos.
References
1. Zissimopoulos J.M., et al. The impact of changes in population health and mortality on future prevalence
of Alzheimer’s disease and other dementias in the United States. The Journals of Gerontology: Series
B, 2018. 73(suppl_1): p. S38–S47.
2. Chen C. and Zissimopoulos J.M., Racial and ethnic differences in trends in dementia prevalence and
risk factors in the United States. Alzheimer’s & Dementia: Translational Research & Clinical Interven-
tions, 2018. 4: p. 510–520.
3. Lourida I., et al. Association of Lifestyle and Genetic Risk With Incidence of Dementia. JAMA, 2019.
4. World Health Organization, Risk reduction of cognitive decline and dementia: WHO guidelines, in Risk
reduction of cognitive decline and dementia: WHO guidelines. 2019. https://doi.org/10.1177/
1471301217699675
5. Livingston G., et al. Dementia prevention, intervention, and care. The Lancet, 2017. 390(10113): p.
2673–2734.
6. Zissimopoulos J., Crimmins E. and St Clair P., The Value of Delaying Alzheimer’s Disease Onset.
Forum for Health Economics and Policy, 2015. 18(1): p. 25–39.
7. Chong P.H., Seeger J.D. and Franklin C., Clinically relevant differences between the statins: implica-
tions for therapeutic selection. The American Journal of Medicine, 2001. 111(5): p. 390–400. https://
doi.org/10.1016/s0002-9343(01)00870-1 PMID: 11583643
8. Kandiah N. and Feldman H.H., Therapeutic potential of statins in Alzheimer’s disease. Journal of the
Neurological Sciences, 2009. 283(1): p. 230–234.
9. Reed B., et al. Low HDL and High LDL Serum Cholesterol Are Associated With Cerebral Amyloidosis.
JAMA Neurology, 2014. 71(2): p. 195. https://doi.org/10.1001/jamaneurol.2013.5390 PMID: 24378418
10. Lesser G., et al. Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neu-
rofibrillary tangles. Current Alzheimer Research, 2011. 8(3): p. 303. https://doi.org/10.2174/
156720511795563755 PMID: 21244352
11. Petanceska S.S., et al. Statin therapy for Alzheimer’s disease. Journal of Molecular Neuroscience,
2002. 19(1–2): p. 155–161. https://doi.org/10.1007/s12031-002-0026-2 PMID: 12212773
12. Refolo L.M., et al. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse
model of Alzheimer’s disease. Neurobiology of Disease, 2001. 8(5): p. 890–899. https://doi.org/10.
1006/nbdi.2001.0422 PMID: 11592856
PLOS ONE Combination statin and antihypertensive therapy and Alzheimer’s disease and related dementia risk
PLOS ONE | https://doi.org/10.1371/journal.pone.0229541 March 4, 2020 12 / 15
13. Richardson K., et al. Statins and cognitive function: a systematic review. Annals of Internal Medicine,
2013. 159(10): p. 688–697. https://doi.org/10.7326/0003-4819-159-10-201311190-00007 PMID:
24247674
14. Shepardson N.E., Shankar G.M. and Selkoe D.J., Cholesterol level and statin use in Alzheimer disease:
II. Review of human trials and recommendations. Archives of Neurology, 2011. 68(11): p. 1385–1392.
https://doi.org/10.1001/archneurol.2011.242 PMID: 22084122
15. Schultz B.G., Patten D.K. and Berlau D.J., The role of statins in both cognitive impairment and protec-
tion against dementia: a tale of two mechanisms. Translational Neurodegeneration, 2018. 7(1): p. 5.
16. Zissimopoulos J.M., et al. Sex and Race Differences in the Association Between Statin Use and the
Incidence of Alzheimer Disease. JAMA Neurology, 2017. 74(2): p. 225–232. https://doi.org/10.1001/
jamaneurol.2016.3783 PMID: 27942728
17. Redelmeier D.A., Manzoor F. and Thiruchelvam D., Association Between Statin Use and Risk of
Dementia After a Concussion. JAMA Neurology, 2019.
18. Haag M.D., et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophili-
city. The Rotterdam Study. Journal of Neurology, Neurosurgery & Psychiatry, 2009. 80(1): p. 13–17.
19. Jick H., et al. Statins and the risk of dementia. The Lancet, 2000. 356(9242): p. 1627–1631.
20. Li G., et al. Age-Varying Association Between Statin Use and Incident Alzheimer’s Disease. Journal of
the American Geriatrics Society, 2010. 58(7): p. 1311–1317. https://doi.org/10.1111/j.1532-5415.2010.
02906.x PMID: 20533968
21. Lin F.-C., et al. Early Statin Use and the Progression of Alzheimer Disease: A Total Population-Based
Case-Control Study. Medicine, 2015. 94(47): p. e2143. https://doi.org/10.1097/MD.
0000000000002143 PMID: 26632742
22. Wolozin B., et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson’s dis-
ease. BMC Medicine, 2007. 5(1): p. 1.
23. Geifman N., et al. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s dis-
ease. Alzheimer’s Research & Therapy, 2017. 9(1): p. 10.
24. Geifman N., et al. Data-driven identification of endophenotypes of Alzheimer’s disease progression:
implications for clinical trials and therapeutic interventions. Alzheimer’s Research & Therapy, 2018. 10
(1): p. 4.
25. Li G., et al. Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults.
Neurology, 2017. 89(12): p. 1251–1255. https://doi.org/10.1212/WNL.0000000000004392 PMID:
28821686
26. Li G., et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease.
Neurology, 2007. 69(9): p. 878–885. https://doi.org/10.1212/01.wnl.0000277657.95487.1c PMID:
17724290
27. Rouch L., et al. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic
review of observational studies, randomized controlled trials and meta-analyses, with discussion of
potential mechanisms. CNS Drugs, 2015. 29(2): p. 113–130. https://doi.org/10.1007/s40263-015-
0230-6 PMID: 25700645
28. Marpillat N.L., et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network
meta-analysis. Journal of Hypertension, 2013. 31(6): p. 1073–1082. https://doi.org/10.1097/HJH.
0b013e3283603f53 PMID: 23552124
29. Peters R., et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly
Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. The Lancet
Neurology, 2008. 7(8): p. 683–689. https://doi.org/10.1016/S1474-4422(08)70143-1 PMID: 18614402
30. van Charante E.P.M., et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent
dementia (preDIVA): a cluster-randomised controlled trial. The Lancet, 2016. 388(10046): p. 797–805.
31. Miners J., et al. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer’s disease, and
relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathology and Applied Neuro-
biology, 2008. 34(2): p. 181–193. https://doi.org/10.1111/j.1365-2990.2007.00885.x PMID: 17973905
32. Miners S., et al. Angiotensin-converting enzyme levels and activity in Alzheimer’s disease: differences
in brain and CSF ACE and association with ACE1 genotypes. American Journal of Translational
Research, 2009. 1(2): p. 163. PMID: 19956428
33. Miners J.S., et al. Aβ-degrading enzymes: potential for treatment of Alzheimer disease. Journal of Neu-
ropathology & Experimental Neurology, 2011. 70(11): p. 944–959.
34. Kehoe P.G., et al. Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association
with increasing amyloid-β and tau pathology. Alzheimer’s Research & Therapy, 2016. 8(1): p. 50.
PLOS ONE Combination statin and antihypertensive therapy and Alzheimer’s disease and related dementia risk
PLOS ONE | https://doi.org/10.1371/journal.pone.0229541 March 4, 2020 13 / 15
35. Kehoe P.G., The coming of age of the angiotensin hypothesis in Alzheimer’s disease–progress towards
disease prevention and treatment? Journal of Alzheimer’s Disease, 2018. 62(3).
36. Kehoe P.G. and Wilcock G.K., Is inhibition of the renin–angiotensin system a new treatment option for
Alzheimer’s disease? The Lancet Neurology, 2007. 6(4): p. 373–378. https://doi.org/10.1016/S1474-
4422(07)70077-7 PMID: 17362841
37. Kehoe P.G., Miners S. and Love S., Angiotensins in Alzheimer’s disease–friend or foe? Trends in Neu-
rosciences, 2009. 32(12): p. 619–628. https://doi.org/10.1016/j.tins.2009.07.006 PMID: 19796831
38. Wharton W., et al. Neurofibrillary Tangles and Conversion to Mild Cognitive Impairment with Certain
Antihypertensives. Journal of Alzheimer’s Disease, 2019(Preprint): p. 1–9.
39. Wharton W., et al. Modulation of Renin-Angiotensin System May Slow Conversion from Mild Cognitive
Impairment to Alzheimer’s Disease. Journal of the American Geriatrics Society, 2015. 63(9): p. 1749–
1756. https://doi.org/10.1111/jgs.13627 PMID: 26389987
40. Hajjar I., et al. Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large
brain autopsy series. Archives of Neurology, 2012. 69(12): p. 1632–1638. https://doi.org/10.1001/
archneurol.2012.1010 PMID: 22964777
41. Hajjar I., et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive
impairment: results of a pilot randomized clinical trial. Journal of the American Geriatrics Society, 2013.
61(2): p. 194–201. https://doi.org/10.1111/jgs.12100 PMID: 23350899
42. Li N.-C., et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male popu-
lation: prospective cohort analysis. BMJ, 2010. 340: p. b5465. https://doi.org/10.1136/bmj.b5465
PMID: 20068258
43. Evans C.E., et al. Exploring ACE-2 as a novel therapeutic target for Alzheimer’s disease. Alzheimer’s &
Dementia: The Journal of the Alzheimer’s Association, 2018. 14(7): p. P1659.
44. Barthold D., et al. The association of multiple anti-hypertensive medication classes with Alzheimer’s dis-
ease incidence across sex, race, and ethnicity. PLOS ONE, 2018. 13(11).
45. Neuman P. and Jacobson G., Medicare Advantage Checkup. The New England Journal of Medicine,
2018. 379(22): p. 2163–2172. https://doi.org/10.1056/NEJMhpr1804089 PMID: 30428276
46. Li P., Kim M.M. and Doshi J.A., Comparison of the performance of the CMS Hierarchical Condition Cat-
egory (CMS-HCC) risk adjuster with the Charlson and Elixhauser comorbidity measures in predicting
mortality. BMC Health Services Research, 2010. 10(1): p. 1.
47. Bonito A., et al. Creation of new race-ethnicity codes and socioeconomic status (SES) indicators for
Medicare beneficiaries. 2008, Agency for Healthcare Research and Quality, and Center for Medicare
and Medicaid Services: Rockville, MD.
48. Aitken M., et al. Medicines use and spending in the US: a review of 2016 and outlook to 2021. Parsip-
pany: IMS Institute for Healthcare Informatics, 2016.
49. Long D. Global Generic and Biosimilars Trends and Insights. in Association for Accesible Medicines.
2018. IQVIA.
50. Luvai A., et al. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular
disease. Clinical Medicine Insights: Cardiology, 2012. 6: p. CMC. S4324.
51. White C.M., A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. The Journal
of Clinical Pharmacology, 2002. 42(9): p. 963–970. PMID: 12211221
52. Ferdinand K.C., et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-
American patients in a six-week trial. The American Journal of Cardiology, 2006. 97(2): p. 229–235.
https://doi.org/10.1016/j.amjcard.2005.08.026 PMID: 16442368
53. Flockhart, D.A. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School
of Medicine 2007 September 1, 2019]; Available from: https://drug-interactions.medicine.iu.edu
54. Benedet A.L., et al. CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and post-
mortem. Neurology Genetics, 2018. 4(1): p. e216. https://doi.org/10.1212/NXG.0000000000000216
PMID: 29473050
55. ALZGENE. Chromosome 10: Location of Published AD Candidate Genes. 2019 September 1, 2019];
Available from: http://www.alzgene.org/chromo.asp?c=10
56. Wang D., et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin
drugs. The Pharmacogenomics Journal, 2011. 11(4): p. 274. https://doi.org/10.1038/tpj.2010.28 PMID:
20386561
57. McGraw J. and Waller D., Cytochrome P450 variations in different ethnic populations. Expert opinion
on drug metabolism & toxicology, 2012. 8(3): p. 371–382.
PLOS ONE Combination statin and antihypertensive therapy and Alzheimer’s disease and related dementia risk
PLOS ONE | https://doi.org/10.1371/journal.pone.0229541 March 4, 2020 14 / 15
58. Jacobsen W., et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of
the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug
Metabolism and Disposition, 1999. 27(2): p. 173–179. PMID: 9929499
59. Xu J., et al. Graded perturbations of metabolism in multiple regions of human brain in Alzheimer’s dis-
ease: Snapshot of a pervasive metabolic disorder. Biochimica et Biophysica Acta (BBA)-Molecular
Basis of Disease, 2016. 1862(6): p. 1084–1092.
60. Vaughan C.J. and Gotto A.M. Jr, Update on statins: 2003. Circulation, 2004. 110(7): p. 886–892.
https://doi.org/10.1161/01.CIR.0000139312.10076.BA PMID: 15313959
61. Deane, R., et al., Clearance of amyloid-β peptide across the blood-brain barrier: implication for thera-
pies in Alzheimer’s disease. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Tar-
gets-CNS & Neurological Disorders), 2009. 8(1): p. 16–30.
62. Nasrallah I.M., et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral White
Matter Lesions. JAMA, 2019. 322(6): p. 524–534. https://doi.org/10.1001/jama.2019.10551 PMID:
31408137
PLOS ONE Combination statin and antihypertensive therapy and Alzheimer’s disease and related dementia risk
PLOS ONE | https://doi.org/10.1371/journal.pone.0229541 March 4, 2020 15 / 15
